HUMA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
406.0K
-18.0%
495.0K
+6.0%
467.0K
-38.0%
753.0K
+150.2%
301.0K
Cost of Revenue
1.2M
-39.6%
2.0M
-77.6%
9.1M
+3393.1%
260.0K
+22.1%
213.0K
Gross Profit
-825000
+46.5%
-1543000
+82.1%
-8615000
-1847.5%
493.0K
+460.2%
88.0K
Operating Expenses
28.9M
+5.5%
27.4M
+23.3%
22.2M
-10.7%
24.9M
-29.5%
35.3M
R&D
18.1M
-6.8%
19.5M
+33.3%
14.6M
-15.4%
17.3M
-21.5%
22.0M
SG&A
8.0M
+1.2%
7.9M
+4.1%
7.6M
+0.1%
7.6M
-2.5%
7.8M
Operating Income
-29714000
-2.7%
-28935000
+6.2%
-30836000
-26.4%
-24390000
+30.7%
-35197000
EBITDA
-28377000
-2.8%
-27593000
+11.2%
-31065000
-44.6%
-21478000
+36.6%
-33860000
Net Income
-36802000
-108.9%
-17619000
+29.0%
-24804000
-41.7%
-17510000
+53.5%
-37658000
EPS (Basic)
$-0.16
-77.8%
$-0.09
+30.8%
$-0.13
-18.2%
$-0.11
+54.2%
$-0.24
EPS (Diluted)
$-0.16
-77.8%
$-0.09
+30.8%
$-0.13
-18.2%
$-0.11
+54.2%
$-0.24
Shares (Diluted)
234.2M
+18.4%
197.8M
+5.7%
187.1M
+18.2%
158.3M
+1.9%
155.4M
Humacyte (HUMA) โ€” Financials